NCT06321562 - Safety and Tolerability of a Timolol Releasing Intraocular Implant in Subjects With Primary Open-angle Glaucoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

June 26, 2025

Study Completion Date

June 26, 2025

Conditions

Primary Open-angle Glaucoma

Interventions

DRUG

TimoD implant

Consists of 1 TimoD implant administration in the study eye

DEVICE

Injector system

"This is a CE-marked injector intended for intraocular lens (IOL) delivery. In this study, the injector is used as anintraocular implant injection system outside of its scope of intended use."

Trial Locations (5)

39120

Universitätsaugenklinik Magdeburg, Magdeburg

40212

Breyer, Kaymak & Klabe Augenchirurgie, Düsseldorf

66280

Augenklinik Sulzbach, Sulzbach

69120

Universitäts-Augenklinik Heidelberg, Heidelberg

72076

Universitäts-Augenklinik Tübingen, Tübingen